Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides

    loading  Checking for direct PDF access through Ovid

Abstract

Background

Tumor stage and folliculotropic mycosis fungoides are uncommon subtypes of cutaneous T-cell lymphoma (CTCL) with an aggressive disease course. Romidepsin is a histone deacetylase inhibitor approved by the US Food and Drug Administration for patients with CTCL who have received ≥ 1 previous systemic therapy. In the present study, we examined the efficacy and safety of romidepsin in patients from the pivotal, single-arm, open-label, phase II study of relapsed or refractory CTCL with cutaneous tumors and/or folliculotropic disease involvement.

Materials and Methods

Patients with CTCL who had received ≥ 1 previous systemic therapy received romidepsin at 14 mg/m2 on days 1, 8, and 15 of 28-day cycles. Responses were determined by a composite endpoint (assessments of the skin, blood, and lymph nodes). Patients with cutaneous tumors and/or folliculotropic disease involvement were identified by review of diagnosis and histology reports.

Results

The objective response rate to romidepsin was 45% in patients with cutaneous tumors (n = 20) and 60% in patients with folliculotropic disease involvement (n = 10).

Conclusion

Romidepsin is active in subtypes of CTCL with less favorable outcomes, such as tumor stage and folliculotropic mycosis fungoides.

Micro-Abstract

Patients with cutaneous T-cell lymphoma (CTCL) who have cutaneous tumors or folliculotropic disease involvement typically have a poor prognosis. Analysis of the pivotal phase II trial of romidepsin for relapsed or refractory CTCL showed that single-agent romidepsin induced a clinical response or stable disease in most patients with cutaneous tumors and/or folliculotropic disease involvement, supporting its use in these patient populations.

Related Topics

    loading  Loading Related Articles